Stock CATX PERSPECTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Market Closed - Nyse
Other stock markets
 21:00:00 13/05/2024 BST 		Pre-market 14:25:10
1.74 USD -0.57% Intraday chart for Perspective Therapeutics, Inc. 1.705 -2.01%
01:52pm RBC Starts Perspective Therapeutics With Outperform Rating, $3 Price Target MT
05-09 Cantor Fitzgerald Starts Perspective Therapeutics With Overweight Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RBC Starts Perspective Therapeutics With Outperform Rating, $3 Price Target
MT
Cantor Fitzgerald Starts Perspective Therapeutics With Overweight Rating
MT
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
AQ
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
GL
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
GL
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
GL
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
AQ
Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry
CI
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Perspective Therapeutics : Unaudited Pro Forma Condensed Consolidated Financial Information - Form 8-K
PU
B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating
MT
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
GL
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating
MT
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
AQ
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Markets Steady -2-
DJ
North American Morning Briefing : Stock Futures -2-
DJ
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CATX Stock
  4. News Perspective Therapeutics, Inc.